In a CT26 murine colon tumor model, this strategy not only improved the tolerance of ICB therapy without inducing Th17 cells accumulation in spleen, but also achieved potent PD-L1 inhibition to potentiate oxaliplatin (OXA)-mediated chemotherapy (53). The gene discussed is CD274; the disease is colonic neoplasm.